Avidity Biosciences (RNA) Enterprise Value (2019 - 2025)
Avidity Biosciences (RNA) has disclosed Enterprise Value for 7 consecutive years, with -$1.7 billion as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value fell 13.01% year-over-year to -$1.7 billion, compared with a TTM value of -$1.7 billion through Dec 2025, down 13.01%, and an annual FY2025 reading of -$1.7 billion, down 13.01% over the prior year.
- Enterprise Value was -$1.7 billion for Q4 2025 at Avidity Biosciences, up from -$1.9 billion in the prior quarter.
- Across five years, Enterprise Value topped out at -$279.5 million in Q2 2021 and bottomed at -$1.9 billion in Q3 2025.
- Average Enterprise Value over 5 years is -$834.0 million, with a median of -$590.8 million recorded in 2023.
- The sharpest move saw Enterprise Value grew 20.71% in 2021, then tumbled 192.78% in 2024.
- Year by year, Enterprise Value stood at -$405.5 million in 2021, then plummeted by 50.59% to -$610.7 million in 2022, then grew by 2.52% to -$595.4 million in 2023, then crashed by 152.2% to -$1.5 billion in 2024, then dropped by 13.01% to -$1.7 billion in 2025.
- Business Quant data shows Enterprise Value for RNA at -$1.7 billion in Q4 2025, -$1.9 billion in Q3 2025, and -$1.2 billion in Q2 2025.